Business
HLS Therapeutics Announces that Icosapent Ethyl (Vascepa®) is Included in the 2021 Canadian Cardiovascular Society (CCS) Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults
HLS Therapeutics Announces that Icosapent Ethyl (Vascepa®) is Included in the 2021 C...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n \n \n \n HLS Therapeutics Announces that Icosapent Ethyl (Vascepa®) is Included in the 2021 Canadian Cardiovascular Society (CCS) Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; VERTICAL-ALIGN: TOP; BORDER-BOTTOM:black 0pt; TEXT-ALIGN: LEFT; PADDING-LEFT:0.50em; BORDER-LEFT:black 0pt; PADDING-RIGHT:0.50em\n}\n.prnbcc{\nBORDER-TOP:0pt solid; BORDER-RIGHT:0pt solid; BORDER-COLLAPSE: COLLAPSE; BORDER-BOTTOM:0pt solid; BORDER-LEFT:0pt solid\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n \n CCS dyslipidemia management guidelines published in the Canadian Journal of Cardiology (CJC) on\n \n March 26, 2021\n \n \n \n \n \n \n \n Strong recommendation for the use of icosapent ethyl for Primary Prevention (diabetes and ≥1 cardiovascular disease (CVD) risk factors) and Secondary Prevention (atherosclerotic cardiovascular disease (ASCVD))\n \n \n \n \n \n \n Guidelines do not recommend the use of over-the-counter omega-3 polyunsaturated fatty acids supplements to reduce CVD risk\n \n \n \n \n \n \n TORONTO\n \n ,\n \n March 29, 2021\n \n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that the Canadian Cardiovascular Society (\"CCS\") has included icosapent ethyl (Vascepa) in its 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult, published in the Canadian Journal of Cardiology. The guideline authors recommend the use of icosapent ethyl to lower the risk of cardiovascular (\"CV\") events in patients with ASCVD, or with diabetes and ≥1 CVD risk factors, who have an elevated fasting triglyceride level between 1.5-5.6 mmol/L despite treatment with maximally tolerated statin therapy.  The Guidelines specifically do not recommend the use of over-the-counter omega-3 polyunsaturat...